Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,533
archived clinical trials in
Kidney Cancer

Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
A Phase II Study Of Aerosolized GM-CSF In The Treatment Of Metastatic Renal Cell Carcinoma To The Lung
Status: Enrolling
Updated:  7/12/2016
CCOP - Sioux Community Cancer Consortium
1314
mi
from 91732
Sioux Falls, SD
Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
A Phase II Study Of Aerosolized GM-CSF In The Treatment Of Metastatic Renal Cell Carcinoma To The Lung
Status: Enrolling
Updated: 7/12/2016
CCOP - Sioux Community Cancer Consortium
1314
mi
from 91732
Sioux Falls, SD
Click here to add this to my saved trials
Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
A Phase II Study Of Aerosolized GM-CSF In The Treatment Of Metastatic Renal Cell Carcinoma To The Lung
Status: Enrolling
Updated:  7/12/2016
Central Plains Clinic, Ltd.
1313
mi
from 91732
Sioux Falls, SD
Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
A Phase II Study Of Aerosolized GM-CSF In The Treatment Of Metastatic Renal Cell Carcinoma To The Lung
Status: Enrolling
Updated: 7/12/2016
Central Plains Clinic, Ltd.
1313
mi
from 91732
Sioux Falls, SD
Click here to add this to my saved trials
Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
A Phase II Study Of Aerosolized GM-CSF In The Treatment Of Metastatic Renal Cell Carcinoma To The Lung
Status: Enrolling
Updated:  7/12/2016
Saskatchewan Cancer Agency
1317
mi
from 91732
Regina,
Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
A Phase II Study Of Aerosolized GM-CSF In The Treatment Of Metastatic Renal Cell Carcinoma To The Lung
Status: Enrolling
Updated: 7/12/2016
Saskatchewan Cancer Agency
1317
mi
from 91732
Regina,
Click here to add this to my saved trials
A Prospective Pilot Study Evaluating Renal Lesions Through Contrast-enhanced Ultrasound (US) in Patients With Renal Cancer and in Those With a Risk Factor for Renal Malignancy
LCCC 1219: A Prospective Pilot Study Evaluating Renal Lesions Through Contrast-enhanced US in Patients With Renal Cancer and in Those With a Risk Factor for Renal Malignancy
Status: Enrolling
Updated:  11/22/2016
Lineberger Comprehensive Cancer Center
2189
mi
from 91732
Chapel Hill, NC
A Prospective Pilot Study Evaluating Renal Lesions Through Contrast-enhanced Ultrasound (US) in Patients With Renal Cancer and in Those With a Risk Factor for Renal Malignancy
LCCC 1219: A Prospective Pilot Study Evaluating Renal Lesions Through Contrast-enhanced US in Patients With Renal Cancer and in Those With a Risk Factor for Renal Malignancy
Status: Enrolling
Updated: 11/22/2016
Lineberger Comprehensive Cancer Center
2189
mi
from 91732
Chapel Hill, NC
Click here to add this to my saved trials
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated:  12/12/2016
City of Hope Comprehensive Cancer Center
4
mi
from 91732
Duarte, CA
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated: 12/12/2016
City of Hope Comprehensive Cancer Center
4
mi
from 91732
Duarte, CA
Click here to add this to my saved trials
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated:  12/12/2016
U.S.C./Norris Comprehensive Cancer Center
11
mi
from 91732
Los Angeles, CA
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated: 12/12/2016
U.S.C./Norris Comprehensive Cancer Center
11
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated:  12/12/2016
Tower Cancer Research Foundation
21
mi
from 91732
Beverly Hills, CA
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated: 12/12/2016
Tower Cancer Research Foundation
21
mi
from 91732
Beverly Hills, CA
Click here to add this to my saved trials
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated:  12/12/2016
University of California-Davis Comprehensive Cancer Ctr
363
mi
from 91732
Sacramento, CA
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated: 12/12/2016
University of California-Davis Comprehensive Cancer Ctr
363
mi
from 91732
Sacramento, CA
Click here to add this to my saved trials
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated:  12/12/2016
City of Hope South Pasadena
8
mi
from 91732
South Pasadena, CA
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated: 12/12/2016
City of Hope South Pasadena
8
mi
from 91732
South Pasadena, CA
Click here to add this to my saved trials
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated:  12/12/2016
Penn State Hershey Cancer Institute-Clinical Trials Office
2295
mi
from 91732
Hershey, PA
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated: 12/12/2016
Penn State Hershey Cancer Institute-Clinical Trials Office
2295
mi
from 91732
Hershey, PA
Click here to add this to my saved trials
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated:  12/12/2016
University of Pittsburgh Cancer Institute (UPCI)
2122
mi
from 91732
Pittsburgh, PA
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated: 12/12/2016
University of Pittsburgh Cancer Institute (UPCI)
2122
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated:  12/12/2016
M D Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Status: Enrolling
Updated: 12/12/2016
M D Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Zinc Supplements in Lowering Cadmium Levels in Smokers
Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers?
Status: Enrolling
Updated:  1/18/2017
Wake Forest University Comprehensive Cancer Center
2124
mi
from 91732
Winston-Salem, NC
Zinc Supplements in Lowering Cadmium Levels in Smokers
Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers?
Status: Enrolling
Updated: 1/18/2017
Wake Forest University Comprehensive Cancer Center
2124
mi
from 91732
Winston-Salem, NC
Click here to add this to my saved trials
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
815
mi
from 91732
Englewood, CO
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
815
mi
from 91732
Englewood, CO
Click here to add this to my saved trials
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
1569
mi
from 91732
Woodbury, MN
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
1569
mi
from 91732
Woodbury, MN
Click here to add this to my saved trials
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
2092
mi
from 91732
Rock Hill, NC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
2092
mi
from 91732
Rock Hill, NC
Click here to add this to my saved trials
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
939
mi
from 91732
Tacoma, WA
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
939
mi
from 91732
Tacoma, WA
Click here to add this to my saved trials
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
1908
mi
from 91732
Marietta, GA
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
1908
mi
from 91732
Marietta, GA
Click here to add this to my saved trials
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Phase II Study of Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients With Renal Cell Carcinoma (SPECIAL Trial)
Status: Enrolling
Updated:  2/13/2017
Rutgers Cancer Institute of New Jersey
2410
mi
from 91732
New Brunswick, NJ
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Phase II Study of Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients With Renal Cell Carcinoma (SPECIAL Trial)
Status: Enrolling
Updated: 2/13/2017
Rutgers Cancer Institute of New Jersey
2410
mi
from 91732
New Brunswick, NJ
Click here to add this to my saved trials
Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer
A Pilot Neoadjuvant Clinical Trial With Evaluation of Molecular Effects With Sorafenib Tosylate for Patients With Stage II or Greater Renal Cell Carcinoma
Status: Enrolling
Updated:  4/17/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
2189
mi
from 91732
Chapel Hill, NC
Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer
A Pilot Neoadjuvant Clinical Trial With Evaluation of Molecular Effects With Sorafenib Tosylate for Patients With Stage II or Greater Renal Cell Carcinoma
Status: Enrolling
Updated: 4/17/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
2189
mi
from 91732
Chapel Hill, NC
Click here to add this to my saved trials
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
Phase II Study of CC-5013 in Patients With Advanced Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  4/18/2017
Case Comprehensive Cancer Center
2036
mi
from 91732
Cleveland, OH
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
Phase II Study of CC-5013 in Patients With Advanced Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 4/18/2017
Case Comprehensive Cancer Center
2036
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Status: Enrolling
Updated:  6/26/2017
Mayo Clinic Scottsdale
356
mi
from 91732
Scottsdale, AZ
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Status: Enrolling
Updated: 6/26/2017
Mayo Clinic Scottsdale
356
mi
from 91732
Scottsdale, AZ
Click here to add this to my saved trials
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Status: Enrolling
Updated:  6/26/2017
Mayo Clinic Cancer Center
1524
mi
from 91732
Rochester, MN
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Status: Enrolling
Updated: 6/26/2017
Mayo Clinic Cancer Center
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants
BARC: A Secreted Marker of Kidney Cancer
Status: Enrolling
Updated:  7/31/2017
Wake Forest University Comprehensive Cancer Center
2124
mi
from 91732
Winston-Salem, NC
Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants
BARC: A Secreted Marker of Kidney Cancer
Status: Enrolling
Updated: 7/31/2017
Wake Forest University Comprehensive Cancer Center
2124
mi
from 91732
Winston-Salem, NC
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
New York Medical College
2443
mi
from 91732
Valhalla, NY
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
New York Medical College
2443
mi
from 91732
Valhalla, NY
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Hospital of Philadelphia
2375
mi
from 91732
Philadelphia, PA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Hospital of Philadelphia
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Hospital of Pittsburgh of UPMC
2121
mi
from 91732
Pittsburgh, PA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Hospital of Pittsburgh of UPMC
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Methodist Children's Hospital of South Texas
1182
mi
from 91732
San Antonio, TX
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Methodist Children's Hospital of South Texas
1182
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
University of Alabama at Birmingham
1777
mi
from 91732
Birmingham, AL
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
University of Alabama at Birmingham
1777
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Oncology Group
4
mi
from 91732
Arcadia, CA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Oncology Group
4
mi
from 91732
Arcadia, CA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Loma Linda University Medical Center
43
mi
from 91732
Loma Linda, CA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Loma Linda University Medical Center
43
mi
from 91732
Loma Linda, CA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Hospital Colorado
825
mi
from 91732
Aurora, CO
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Hospital Colorado
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
All Children's Hospital
2130
mi
from 91732
Saint Petersburg, FL
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
All Children's Hospital
2130
mi
from 91732
Saint Petersburg, FL
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Healthcare of Atlanta - Egleston
1922
mi
from 91732
Atlanta, GA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Healthcare of Atlanta - Egleston
1922
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Memorial Hospital
1728
mi
from 91732
Chicago, IL
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Memorial Hospital
1728
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Indiana University Cancer Center
1792
mi
from 91732
Indianapolis, IN
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Indiana University Cancer Center
1792
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Indiana University Medical Center
1793
mi
from 91732
Indianapolis, IN
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Indiana University Medical Center
1793
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Hospital-Main Campus
1655
mi
from 91732
New Orleans, LA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Hospital-Main Campus
1655
mi
from 91732
New Orleans, LA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Johns Hopkins University
2301
mi
from 91732
Baltimore, MD
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Johns Hopkins University
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
C S Mott Children's Hospital
1931
mi
from 91732
Ann Arbor, MI
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
C S Mott Children's Hospital
1931
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Univ of Nebraska Med Ctr
1300
mi
from 91732
Omaha, NE
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Univ of Nebraska Med Ctr
1300
mi
from 91732
Omaha, NE
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Hackensack University Medical Center
2430
mi
from 91732
Hackensack, NJ
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Hackensack University Medical Center
2430
mi
from 91732
Hackensack, NJ
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Columbia University Medical Center
2432
mi
from 91732
New York, NY
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Columbia University Medical Center
2432
mi
from 91732
New York, NY
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Oregon Health and Science University
827
mi
from 91732
Portland, OR
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Oregon Health and Science University
827
mi
from 91732
Portland, OR
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Medical University of South Carolina
2184
mi
from 91732
Charleston, SC
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Medical University of South Carolina
2184
mi
from 91732
Charleston, SC
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
University of Texas Southwestern Medical Center
1225
mi
from 91732
Dallas, TX
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
University of Texas Southwestern Medical Center
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Cook Children's Medical Center
1193
mi
from 91732
Fort Worth, TX
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Cook Children's Medical Center
1193
mi
from 91732
Fort Worth, TX
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Seattle Children's Hospital
964
mi
from 91732
Seattle, WA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Seattle Children's Hospital
964
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Midwest Children's Cancer Center
1729
mi
from 91732
Milwaukee, WI
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Midwest Children's Cancer Center
1729
mi
from 91732
Milwaukee, WI
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's National Medical Center
2281
mi
from 91732
Washington, D.C.,
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's National Medical Center
2281
mi
from 91732
Washington, D.C.,
Click here to add this to my saved trials